Real-world data with the use of caplacizumab in the treatment of acquired thrombotic thrombocytopenic purpura: A single-center with homogeneous treatment experience.
Moraima JiménezSabela BobilloVerónica PonsCarla SánchezAna PérezAntonieta MoleroNayibe MirandaÁngela SánchezElizabeth TabaresFrancesc BoschDavid ValcárcelPublished in: Transfusion (2022)
Our experience confirms improvement in the outcomes with a decrease in refractoriness and mortality since the introduction of caplacizumab.